Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Peters S., Angevin E., Alonso-Gordoa T., Rohrberg K., Melero I., Mellado B., Perez-Gracia J-L., Tabernero J., Adessi C., Boetsch C., Watson C., Dal Porto J., Dejardin D., Del Nagro C., Nicolini V., Evers S., Klein C., Leutgeb B., Pisa P., Rossmann E., Saro J., Umana P., Charo J., Teichgräber V., Steeghs N.
<p>Supplementary Figure S5. The detailed effect of obinutuzumab pretreatment followed by CEA-IL2v on six timepoints from screening to Cycle 4 Day 5 of treatment. A, Peripheral blood natural killer cell count. B, Proliferating peripheral blood CD8+ T-cell count. C, Peripheral blood CD19+ B-cell count. C, cycle; CEA-IL2v, cergutuzumab amunaleukin; D, Day</p>